NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3β Resulting in the Stabilization of MYCN in Human Neuroblastomas

PLoS Genetics

Volumn 10, Issue 1, 2014, Pages

  Suenaga, Yusuke ^a   Islam, S M Rafiqul ^a   Alagu, Jennifer ^a   Kaneko, Yoshiki ^a   Kato, Mamoru ^b   Tanaka, Yukichi ^c   Kawana, Hidetada ^a   Hossain, Shamim ^a,e   Matsumoto, Daisuke ^a   Yamamoto, Mami ^a   Shoji, Wataru ^a,d   Itami, Makiko ^a   Shibata, Tatsuhiro ^b   Nakamura, Yohko ^a   Ohira, Miki ^a   Haraguchi, Seiki ^a,f   Takatori, Atsushi ^a   Nakagawara, Akira ^a  

^a CHIBA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f NATIONAL INSTITUTE OF LIVESTOCK AND GRASSLAND SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DACTOLISIB; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; MYCN PROTEIN; NCYM PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CHIMPANZEE; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENETIC CODE; GENETIC CONSERVATION; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE MYCN; ONCOGENE NCYM; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; SURVIVAL TIME; TRANSACTIVATION; TRANSGENIC MOUSE;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); CELL LINE, TUMOR; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; RNA, MESSENGER;

EID: 84896730858     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003996     Document Type: Article

References (46)

1. Jacob F, (1977) Evolution and tinkering. Science 196: 1161-1166.
2. Ohno S (1970) Evolution by gene duplication. New York, NY, Springer-Verlag.
3. Tautz D, Domazet-Loso T, (2011) The evolutionary origin of orphan genes. Nat Rev Genet 12: 692-702.
4. Kaessmann H, (2010) Origins, evolution, and phenotypic impact of new genes. Genome Res 20: 1313-1326.
5. Khalturin K, Hemmrich G, Fraune S, Augustin R, Bosch TC, (2009) More than just orphans: are taxonomically-restricted genes important in evolution? Trends Genet 25: 404-413.
6. Carvunis AR, Rolland T, Wapinski I, Calderwood MA, Yildirim MA, et al. (2012) Proto-genes and de novo gene birth. Nature 487: 370-374.
7. Li D, Dong Y, Jiang Y, Jiang H, Cai J, et al. (2010) A de novo originated gene depresses budding yeast mating pathway and is repressed by the protein encoded by its antisense strand. Cell Res 20: 408-420.
8. Begun DJ, Lindfors HA, Thompson ME, Holloway AK, (2006) Recently evolved genes identified from Drosophila yakuba and D. erecta accessory gland expressed sequence tags. Genetics 172: 1675-1681.
9. Begun DJ, Lindfors HA, Kern AD, Jones CD, (2007) Evidence for de novo evolution of testis-expressed genes in the Drosophila yakuba/Drosophila erecta clade. Genetics 176: 1131-1137.
10. Cai J, Zhao R, Jiang H, Wang W, (2008) De novo origination of a new protein-coding gene in Saccharomyces cerevisiae. Genetics 179: 487-496.
11. Chen ST, Cheng HC, Barbash DA, Yang HP, (2007) Evolution of hydra, a recently evolved testis-expressed gene with nine alternative first exons in Drosophila melanogaster. PLoS Genet 3: e107.
12. Toll-Riera M, Bosch N, Bellora N, Castelo R, Armengol L, et al. (2009) Origin of primate orphan genes: a comparative genomics approach. Mol Biol Evol 26: 603-612.
13. Knowles DG, McLysaght A, (2009) Recent de novo origin of human protein-coding genes. Genome Res 19: 1752-1759.
14. Li CY, Zhang Y, Wang Z, Cao C, Zhang PW, et al. (2010) A human-specific de novo protein-coding gene associated with human brain functions. PLoS Comput Biol 6: e1000734.
15. O'Bleness M, Searles VB, Varki A, Gagneux P, Sikela JM, (2012) Evolution of genetic and genomic features unique to the human lineage. Nat Rev Genet 13: 853-866.
16. Wu DD, Irwin DM, Zhang YP, (2011) De novo origin of human protein-coding genes. PLoS Genet 7: e1002379.
17. Xie C, Zhang YE, Chen JY, Liu CJ, Zhou WZ, et al. (2012) Hominoid-specific de novo protein-coding genes originating from long non-coding RNAs. PLoS Genet 8: e1002942.
18. Brodeur GM, (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
19. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM, (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124.
20. Schwab M, Varmus HE, Bishop JM, Grzeschik KH, Naylor SL, et al. (1984) Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 308: 288-291.
21. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM, (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985-2995.
22. Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, et al. (2000) MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 18: 3604-3613.
23. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM, (1992) Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 52: 1364-1368.
24. Armstrong BC, Krystal GW, (1992) Isolation and characterization of complementary DNA for N-cym, a gene encoded by the DNA strand opposite to N-myc. Cell Growth Differ 3: 385-390.
25. Krystal GW, Armstrong BC, Battey JF, (1990) N-myc mRNA forms an RNA-RNA duplex with endogenous antisense transcripts. Mol Cell Biol 10: 4180-4191.
26. Jacobs JF, van Bokhoven H, van Leeuwen FN, Hulsbergen-van de Kaa CA, de Vries IJ, et al. (2009) Regulation of MYCN expression in human neuroblastoma cells. BMC Cancer 9: 239.
27. Suenaga Y, Kaneko Y, Matsumoto D, Hossain MS, Ozaki T, et al. (2009) Positive auto-regulation of MYCN in human neuroblastoma. Biochem Biophys Res Commun 390: 21-26.
28. Gustafson WC, Weiss WA, (2010) Myc proteins as therapeutic targets. Oncogene 29: 1249-1259.
29. Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM, (2005) The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell 9: 327-338.
30. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, et al. (2006) MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun 351: 192-197.
31. Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD, (2006) S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 24: 185-197.
32. Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, et al. (2012) Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med 4: 115ra113.
33. Schramm A, Köster J, Marschall T, Martin M, Schwermer M, et al. (2013) Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Int J Cancer 132: E106-115.
34. Johnsen JI, Segerström L, Orrego A, Elfman L, Henriksson M, et al. (2008) Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27: 2910-2922.
35. Yu F, Gao W, Yokochi T, Suenaga Y, Ando K, et al. (2013) RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma. Oncogene [epub ahead of print].
36. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, et al. (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15: 67-78.
37. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, et al. (2012) The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 22: 117-130.
38. Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, et al. (2012) Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med 4: 141ra191.
39. Molenaar JJ, Domingo-Fernandez R, Ebus ME, Lindner S, Koster J, et al. (2012) LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 44: 1199-1206.
40. Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, et al. (2012) Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A 109: 19190-19195.
41. Li Z, Tan F, Thiele CJ, (2007) Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells. Mol Cancer Ther 6: 3113-3121.
42. Kent WJ, (2002) BLAT-the BLAST-like alignment tool. Genome Res 12: 656-664.
43. Blanchette M, Kent WJ, Riemer C, Elnitski L, Smit AF, et al. (2004) Aligning multiple genomic sequences with the threaded blockset aligner. Genome Res 14: 708-715.
44. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402.
45. Wang D, Zhang Y, Zhang Z, Zhu J, Yu J, (2010) KaKs_Calculator 2.0: a toolkit incorporating gamma-series methods and sliding window strategies. Genomics Proteomics Bioinformatics 8: 77-80.
46. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, et al. (2005) Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7: 337-350.